GenoMed, Inc. Announces Publication of Its New Treatment Next Month
ST. LOUIS, July 16 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that results of its novel ACE inhibitor treatment have been accepted for publication.
The article, entitled "From Pharmacogenomics to Improved Patient Outcomes," details the outcomes of 200 African American and Caucasian men with chronic kidney disease due to high blood pressure, diabetes, or polycystic kidney disease, as well as 800 male patients with high blood pressure alone. The study was an observational one; patients were followed over a three year period without being randomized to a "placebo" control.
Highlights of the paper include the following: 1) no adverse events were seen, in large part because the new treatment carefully controlled serum potassium, which is often elevated in patients with kidney failure; 2) African American patients did as well or better than Caucasian patients; 3) if begun early enough, the new treatment could reverse kidney disease in patients with high blood pressure or diabetes.
As seen in other studies, autosomal dominant polycystic kidney disease showed no improvement when treated with higher doses of an ACE inhibitor.
The United States is currently experiencing an epidemic of kidney failure, with a 5% increase annually in the number of patients on kidney dialysis. Minorities are hit especially hard. There are now 200,000 patients on kidney dialysis, at a cost of $18 billion annually. In 2010, it is estimated that there will be 300,000 patients on dialysis, at a much higher cost. Nearly 90% of patients on kidney dialysis lost their kidney function because of diabetes or high blood pressure. About 5% have polycystic kidney disease.
Dr. David Moskowitz, GenoMed's Chairman and Chief Medical Officer, commented, "Publication of our patient outcomes in a peer-reviewed journal is a key step in the validation and dissemination of our novel treatment method. The sooner we can convince patients and physicians about the usefulness of our method, the sooner we believe we can stop the current epidemic in kidney disease."
The article will be published in late August in Diabetes Technology and Therapeutics, a bimonthly journal.
GenoMed has applied for patents on the above material, and expects soon to be enrolling physicians and patients in the U.S. and abroad in its Clinical Outcomes Improvement Progam(TM), based on the Company's discoveries.
About GenoMed
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with a number of common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use. A video version of the company's treatment results for chronic kidney failure is available at 216.234.225.2
Consistent with the Company's goal to improve patient outcomes globally, GenoMed is currently working to license its treatments to physicians and healthcare systems worldwide. GenoMed recently held a press conference at La Clinica Health Center (3646 Fairview Ave., St. Louis, MO; tel. 314-664-5565) in, May 2002 to discuss licensing the same treatment to La Clinica for its Hispanic population, who have a 50% prevalence rate of diabetes. GenoMed also recently announced that it is holding discussions with large physician organizations located in the Midwestern and Southwestern United States as part of its strategy to work directly with physicians to deliver its unique treatments to patients.
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, fax, +1-314-977-0042, email: kfischer@genomedics.comor visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
/CONTACT: Krissy Fischer, GenoMed, Inc., +-1-877-GENOMED, or
fax, +1-314-977-0042, email: kfischer@genomedics.comor/
/Web site: genomedics.com |
